Brenda Deliz
Neurology · Carolina, PRNPI 1023068467
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $5,400 of the $8,989 with a category attached, or 60.1%. PTC Therapeutics, Inc. accounts for 61.4% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2023 at $5,820 and has fallen 91.4% since, to $501 in 2025.
Across 68 payments — averaging $132.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- PTC Therapeutics, Inc.$6K
- Johnson & Johnson$1K
- Novartis$366
- NS Pharma, Inc.$296
- Biogen$271
- AstraZeneca$246
- plus $1K from 15 others
What the payments were for
- Consulting fees$1,02011%
- Speaking & faculty fees$5,40060%
- Food & beverage$2,51128%
- Education$591%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| PTC Therapeutics, Inc. | 5 | $5,516 |
| Johnson & Johnson | 1 | $1,020 |
| Novartis | 15 | $366 |
| NS Pharma, Inc. | 9 | $296 |
| Biogen | 7 | $271 |
| AstraZeneca | 3 | $246 |
| Amgen | 4 | $178 |
| Genentech USA, Inc. | 3 | $167 |
| Tanabe Pharma America, Inc. | 3 | $167 |
| Teva Pharmaceuticals USA, Inc. | 2 | $152 |
| Argenx US, Inc. | 1 | $125 |
| AbbVie(2 entities) | 5 | $124 |
| Eisai Inc. | 1 | $124 |
| Genentech, Inc. | 1 | $54 |
| E.r. Squibb & Sons, L.L.C. | 2 | $42 |
| TG Therapeutics, Inc. | 1 | $34 |
| Sarepta Therapeutics, Inc. | 1 | $33 |
| Eli Lilly Export S.A. Puerto Rico Branch | 1 | $23 |
| Banner Life Sciences, LLC | 1 | $22 |
| Akcea Therapeutics, Inc. | 1 | $15 |
| Acadia Pharmaceuticals Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,989 in reported general payments places this provider in the 85th percentile of 129 neurology providers in Puerto Rico.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 373 | $5,173,675 |
| EvrysdiRisdiplam | 13 | $349,463 |
| RelyvrioSod Phenylbutyrat/Taurursodiol | 24 | $305,206 |
| Riluzole | 193 | $18,866 |
| Glycopyrrolate | 45 | $2,484 |
| Dalfampridine ErDalfampridine | 20 | $1,564 |
| Baclofen | 54 | $1,110 |
| Pyridostigmine Bromide | 18 | $956 |
| Gabapentin | 17 | $364 |
| Clonazepam | 19 | $209 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 12 | $154 |
| Temazepam | 11 | $114 |
| Pantoprazole Sodium | 11 | $113 |
| Famotidine | 11 | $41 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech USA, Inc.Evrysdi | $167 | $349,46313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 129 neurology providers in Puerto Rico.
Other neurology in Carolina
- Karylane Palermo CruzCarolina$5K
- Tania ZayasCarolina$2K
- Angel ChineaGuaynabo$1.7M
- Jose Avila OrnelasCaguas$538K
- Franchesca Fiorito-TorresSan Juan$453K
- Patricia de JesusCaguas$310K
- Mari GarciaSan Juan$138K
- Cristina Cabret-AymatSan Juan$108K
- Gishlaine Alfonso MendezSan Juan$53K
- Laura Surillo-DahdahGuaynabo$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.